Canadian HTA Assessments Recognize Therapeutic Value of QALSODY™ (tofersen injection) and its Potential to Modify Disease Progression in Individuals Living with SOD1-ALS
— CDA issues positive reimbursement recommendation for QALSODY — INESSS recognizes QALSODY's promising clinical value and highlights path toward reimbursement — HTA assessments highlight importance of timely and equitable access to QALSODY for this ultra-rare genetic form of ALS and urgent need for therapies that slow progression, preserve function and independence, extend survival, and improve […]